Paediatric Haematology, Oncology and Stem Cell Transplantation
Thromboembolic diseases and thrombophilia
Thromboembolic events or strokes are relatively rare in children.
Individuals particularly affected include
- Patients with serious and complex pre-existing conditions
- Premature and newborn babies
- Patients with congenital heart defects
- Patients with liver disorders
- Patients with oncological conditions
- Patients with sickle cell disease
- Patients with thalassaemia
The risk of thrombosis increases during adolescence, after the onset of puberty, and mainly occurs in high-risk situations. Spontaneous thrombosis, on the other hand, is rare in children and adolescents and is usually associated with a family history of the condition.
Consultations: We offer consultations for patients with an increased risk of thrombosis and arrange the necessary diagnostics where indicated.
Thrombosis or pulmonary embolism: We initiate age-appropriate anticoagulation therapy and conduct detailed diagnostics to determine the underlying cause of the thrombosis event following the occurrence of thrombosis or pulmonary embolism.
-
- Counselling regarding indications for thrombophilia diagnosis, including genetic counselling and diagnosis if there is a family history of the condition
- Counselling on thrombosis prophylaxis in high-risk situations
- Diagnosis and treatment of children and adolescents with thrombosis or a tendency to thrombosis
- Advice on the type and duration of anticoagulation following thromboembolism
- Monitoring of anticoagulants and antiplatelet agents
- Peri-interventional coagulation management in children undergoing anticoagulant therapy
- Diagnosis and treatment of children and adolescents who have suffered a stroke
-
- Your child does not need to have an empty stomach for the blood test.
- Your child should be free of infection at the time of the examination.
-
- Platelet function inhibitors (e.g. ASA, valproate) -> 10-day break
- Non-steroidal anti-inflammatory medications (e.g. ibuprofen, diclofenac) -> 48-hour break
-
- Vitamin K antagonists: please contact us to discuss whether discontinuation and, where necessary, bridging therapy is required.
- Low molecular weight heparins -> at least 24-hour break
- Direct oral anticoagulants (DOACs) -> at least 24–36-hour break
-
- Previous findings
- Medical referral note with questions and symptoms
